Published Aug 19, 2019

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma

Member News
Copy The Link to the  Article
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Copy The Link to the  Article

Related or similar articles

View more News
May 9, 2019

Labshares Newton Selects Savran Technologies as Winner of First Launch@Labshares Competition Valued at $50K

Second Launch@Shares Competition Announced in Collaboration with MTTC/MALSI Conference and MassBio’s MassCONNECT Program
Press Releases
March 13, 2019

Labshares Newton Grows its Business​

Labshares is unveiling a major rennovation
Labshares News
December 9, 2021

Bulfinch Leases 40,000 Square Feet to Labshares

BOSTON & NEWTON, Mass.--(BUSINESS WIRE)--The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and Labshares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge..
Labshares News